Molecular Templates Inc. Presents Preclinical Data On De-Immunized Engineered Toxin Bodies (ETB) With Novel Immuno-Oncology Capabilities At The 2015 American Association for Cancer Research Annual Meeting

GEORGETOWN, Texas--(BUSINESS WIRE)--Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of next generation immunotoxin therapies called Engineered Toxin Bodies (ETBs) announced today that it will present preclinical data in a poster presentation at the 2015 American Association for Cancer Research (AACR) Meeting in Philadelphia, PA on Monday, April 20th, 2015. In the presentation, entitled “Engineered Toxin Bodies: A next-generation immunotoxin scaffold with novel immuno-oncology functionality” (Abstract 2477), the company reports on the development of proprietarily de-immunized ETBs that can kill tumor cells through an enzymatic shut-down of protein synthesis but can also simultaneously “seed” tumor cells with foreign class I antigens on the target cell surface that can be recognized by high avidity native T-cells. The company is advancing two leads using this technology that target CD38 and HER2.

Help employers find you! Check out all the jobs and post your resume.

Back to news